Core Viewpoint - AirSculpt Technologies reported a decline in revenue and case volume in Q2 FY2025, but management remains optimistic about achieving its full-year guidance despite ongoing challenges in demand and performance [1][12]. Financial Performance - GAAP revenue for Q2 FY2025 was $44.0 million, down 13.7% year-over-year and below analyst expectations of $45.45 million [1][5]. - Diluted EPS was a loss of $0.01, an improvement from a loss of $0.06 in Q2 2024, but below the expected $0.01 [1][2]. - Adjusted EBITDA decreased to $5.8 million from $6.9 million in the same quarter last year, reflecting a 15.0% decline [1][2]. - Case volume fell to 3,392, a 14.1% decrease from the previous year [2][5]. - Adjusted net income was $1.2 million, down 76.8% from $5.1 million in Q2 2024 [2]. Business Overview - AirSculpt Technologies specializes in minimally invasive body contouring procedures, known for avoiding needles and scalpels, appealing to patients seeking less downtime [3]. - The company operates 32 centers in affluent regions across the U.S., Canada, and the UK, focusing on performance, marketing, and innovation [4]. Operational Highlights - The company noted incremental operational progress, with improvements in revenue decline percentages compared to Q1 FY2025 [1][5]. - Average revenue per case remained steady at approximately $12,975, maintaining the company's premium pricing [5]. - Same-center case volume fell 22.0% in Q2 FY2025, indicating challenges in older locations despite overall company growth [10]. Strategic Initiatives - AirSculpt is piloting new offerings, including a standalone skin tightening procedure and expanded consumer financing options [7]. - The company reported a record increase in patient leads, although conversion rates to booked procedures remain slow [8][9]. Financial Management - Long-term debt was reduced by $16 million during Q2 FY2025, with $8.2 million in cash and no outstanding line of credit, enhancing balance sheet strength [11]. - Operating cash flow for the first half of 2025 was $5.9 million, down from $6.8 million in the same period of 2024 [11]. Future Guidance - The company maintained its full-year 2025 revenue guidance of $160 million to $170 million and adjusted EBITDA target of $16 million to $18 million [12]. - Management expressed cautious optimism about achieving annual guidance, contingent on improvements in case volume and lead conversion [12].

[PART I FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents AirSculpt Technologies' unaudited condensed consolidated financial statements as of June 30, 2025, reflecting decreased revenue and net losses compared to prior periods [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of June 30, 2025, shows total assets of $198.4 million, a decrease from $210.0 million at December 31, 2024, with total liabilities decreasing to $107.2 million and total stockholders' equity increasing to $91.2 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 (Unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $16,405 | $17,117 | | **Total Assets** | **$198,367** | **$209,996** | | **Total Current Liabilities** | $25,829 | $28,609 | | **Total Liabilities** | **$107,210** | **$130,706** | | **Total Stockholders' Equity** | **$91,157** | **$79,290** | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q2 2025, the company reported a net loss of $0.6 million on revenue of $44.0 million, while for H1 2025, the net loss was $3.4 million on revenue of $83.4 million, a significant shift from prior-year net income Q2 Operating Results (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue | $44,012 | $51,004 | | Income/(loss) from operations | $786 | $(4,981) | | Net (loss)/income | $(591) | $(3,206) | | Diluted (Loss)/income per share | $(0.01) | $(0.06) | Six-Month Operating Results (in thousands, except per share data) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Revenue | $83,383 | $98,624 | | (Loss)/income from operations | $(803) | $6,031 | | Net (loss)/income | $(3,438) | $2,823 | | Diluted (Loss)/income per share | $(0.06) | $0.05 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash provided by operating activities for H1 2025 was $5.9 million, with net cash used in investing activities decreasing to $2.2 million and financing activities reflecting debt payments offset by public offering proceeds Six-Month Cash Flow Summary (in thousands) | Activity | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $5,852 | $6,807 | | Net cash used in investing activities | $(2,166) | $(5,580) | | Net cash used in financing activities | $(3,732) | $(1,623) | | **Net decrease in cash** | **$(46)** | **$(396)** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, a March 2025 credit agreement amendment, a June 2025 equity offering raising **$13.8 million** in net proceeds, and a **$10.4 million** stock compensation reversal in Q1 2024 - In March 2025, the Company amended its Credit Agreement to modify financial covenants, including the Consolidated Fixed Charge Coverage Ratio and Consolidated Leverage Ratio, and added new liquidity requirements[62](index=62&type=chunk)[64](index=64&type=chunk) - On June 11, 2025, the Company closed an underwritten public offering, receiving net proceeds of approximately **$13.8 million** from the sale of **3,634,000** shares. A portion of the proceeds was used to make a **$10.0 million** principal payment on its term loan[79](index=79&type=chunk)[80](index=80&type=chunk)[66](index=66&type=chunk) - In Q1 2024, the Company recorded a **$10.4 million** cumulative reversal of stock compensation expense related to performance-based stock units (PSUs) after determining the revenue target was improbable to achieve[76](index=76&type=chunk)[19](index=19&type=chunk)[95](index=95&type=chunk) - Advertising expenses decreased to **$7.3 million** in Q2 2025 from **$11.0 million** in Q2 2024, and to **$14.5 million** for H1 2025 from **$19.4 million** in H1 2024[48](index=48&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a revenue decline of **13.7%** for Q2 and **15.5%** for the first six months of 2025, attributed to broader aesthetics industry weakness, and outlines strategies including marketing optimization, sales process improvements, and a **$3.0 million** annual cost reduction program [Overview & Strategic Initiatives](index=27&type=section&id=Overview%20%26%20Strategic%20Initiatives) The company experienced a revenue decline of approximately **14%** in Q2 2025 and **15%** in H1 2025 year-over-year, prompting strategic initiatives focused on marketing, sales, customer experience, financing, and new product innovation, alongside a **$3.0 million** cost reduction program and a pause on new center openings - The company has launched several strategic priorities to stabilize revenue growth, including: - Optimizing marketing investment with a returns-based approach - Improving go-to-market and sales strategies under a new Chief Sales Officer - Enhancing the customer experience - Expanding consumer financing offerings - Focusing on new product innovation, such as a standalone skin tightening procedure[102](index=102&type=chunk)[104](index=104&type=chunk) - A cost reduction program has been implemented to eliminate approximately **$3.0 million** in annual overhead and contracted expenses, and the company has paused de novo center and new procedure room openings[102](index=102&type=chunk) [Key Operational and Business Metrics](index=27&type=section&id=Key%20Operational%20and%20Business%20Metrics) Total cases decreased by **14.1%** in Q2 2025 and **15.9%** in H1 2025, with same-center cases declining more significantly by **22.0%** and **23.1%**, while revenue per case saw a slight increase and the company expanded to **32** facilities Total Case and Revenue Metrics | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Cases | 3,392 | 3,949 | 6,468 | 7,695 | | Case growth | (14.1)% | N/A | (15.9)% | N/A | | Revenue per case | $12,975 | $12,916 | $12,892 | $12,817 | | Number of facilities | 32 | 27 | 32 | 27 | Same-Center Case Metrics | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Cases | 3,079 | 3,949 | 5,916 | 7,695 | | Case growth | (22.0)% | N/A | (23.1)% | N/A | [Non-GAAP Financial Measures](index=28&type=section&id=Non-GAAP%20Financial%20Measures) Adjusted EBITDA for Q2 2025 was **$5.8 million** (**13.3%** margin), down from **$6.9 million** (**13.5%** margin) in Q2 2024, and for H1 2025, it was **$9.6 million** (**11.5%** margin), down from **$14.2 million** (**14.4%** margin) in H1 2024 Adjusted EBITDA Reconciliation (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Net (loss)/income | $(591) | $(3,206) | $(3,438) | $2,823 | | **Adjusted EBITDA** | **$5,835** | **$6,868** | **$9,590** | **$14,205** | | **Adjusted EBITDA Margin** | **13.3%** | **13.5%** | **11.5%** | **14.4%** | Adjusted Net Income Reconciliation (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Net (loss)/income | $(591) | $(3,206) | $(3,438) | $2,823 | | **Adjusted net income** | **$1,187** | **$5,140** | **$79** | **$7,020** | | **Adjusted net income per share (Diluted)** | **$0.02** | **$0.09** | **$0.00** | **$0.12** | [Results of Operations](index=31&type=section&id=Results%20of%20Operations) Q2 2025 revenue decreased by **$7.0 million** (**13.7%**) due to lower case volume, while SG&A expenses decreased by **$11.6 million** (**33.9%**) primarily from reduced advertising, stock compensation, and severance costs, and cost of service as a percentage of revenue increased - Q2 2025 revenue decreased by **$7.0 million** (**13.7%**) YoY, attributed to weaker performance across the broader aesthetics industry[126](index=126&type=chunk) - Q2 2025 Selling, General and Administrative (SG&A) expenses decreased by **$11.6 million** (**33.9%**) YoY, driven by lower advertising costs (**$3.4M**), stock compensation (**$3.5M**), and severance costs (**$3.7M**)[128](index=128&type=chunk)[129](index=129&type=chunk) - H1 2025 revenue decreased by **$15.2 million** (**15.5%**) YoY, also attributed to weaker industry performance[135](index=135&type=chunk) [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company had **$8.2 million** in cash and cash equivalents and **$5.0 million** available on its revolving credit facility, bolstered by a June 2025 equity offering that raised **$13.8 million** in net proceeds, used partly for debt repayment, and a March 2025 credit agreement amendment - As of June 30, 2025, the company had **$8.2 million** in cash and cash equivalents and **$5.0 million** available under its revolving credit facility[146](index=146&type=chunk) - In June 2025, the company completed a follow-on equity offering, raising net proceeds of approximately **$13.8 million**, and used the proceeds to make a **$10.0 million** principal payment on its term loan[157](index=157&type=chunk)[166](index=166&type=chunk) - The company amended its credit agreement in March 2025, modifying financial covenants, increasing interest rate margins, and shortening the maturity date to May 11, 2027[164](index=164&type=chunk)[165](index=165&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is a smaller reporting company and is not required to provide the information for this item - The company is exempt from this disclosure requirement as it qualifies as a smaller reporting company[170](index=170&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting identified during the quarter - Management concluded that disclosure controls and procedures were effective as of June 30, 2025[172](index=172&type=chunk) - No material changes in internal control over financial reporting were identified during the quarter ended June 30, 2025[173](index=173&type=chunk) [PART II OTHER INFORMATION](index=44&type=section&id=PART%20II%20OTHER%20INFORMATION) [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in ordinary course legal actions, primarily related to medical malpractice claims, which are not expected to have a material adverse effect on its financial condition and are generally covered by insurance - The company faces routine legal actions, mainly medical malpractice claims, which are not expected to have a material adverse impact on its financial condition, results of operations, or cash flows[178](index=178&type=chunk) [Risk Factors](index=44&type=page&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2024 - No material changes to risk factors were reported since the Annual Report on Form 10-K for the year ended December 31, 2024[179](index=179&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - None reported for the period[180](index=180&type=chunk) [Other Information](index=44&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated any Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025 - No directors or officers adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" during the quarter[183](index=183&type=chunk) [Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including officer certifications pursuant to Sarbanes-Oxley Act sections 302 and 906, and Inline XBRL data files - The report includes required certifications from the Principal Executive Officer and Principal Financial Officer, as well as Inline XBRL documents, as filed exhibits[185](index=185&type=chunk)

AirSculpt (AIRS) Q2 2025 Earnings Call August 01, 2025 08:30 AM ET Speaker0Greetings, and welcome to the AirSculpt Technologies Incorporated Second Quarter twenty twenty five Earnings Conference Call. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I would now like to turn the conference over to Allison Malkin, Partner of ICR.Speaker1Good morning, everyone. Thank you for joining us to disc ...

AirSculpt Technologies, Inc. (AIRS) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of +33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.AirSculpt Technolog ...

"In the quarter, we began to pilot two new offerings - skin tightening, a core competency of ours that capitalizes on the skin laxity associated with the use of GLP-1's - and an expansion in our financing options to provide greater flexibility for consumers. These are examples of our enhanced growth strategy and, alongside our elevated go-to market processes, increase our confidence in our ability to accelerate our comparable sales improvement throughout the year. Importantly, we have strengthened our balan ...

Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures, focusing on next-generation treatments that optimize comfort and precision [3]. Financial Results Announcement - AirSculpt will report its second quarter 2025 financial results before the market opens on August 1, 2025, followed by a conference call at 8:30 a.m. Eastern Time on the same day [1]. Conference Call Details - The conference call can be accessed via a toll-free domestic number (1-877-407-9716) or an international number (1-201-493-6779) using the conference ID 13754561, with a live webcast available on the investor relations section of the AirSculpt website [2].

Programming Update - Nickelodeon has added two new animated series, Unicorn Academy and Vida the Vet, to its programming lineup starting July 2025, marking their linear debuts in the U.S. [1] - Unicorn Academy follows the adventures of Sophia and her classmates at a magical boarding school on Unicorn Island, focusing on themes of friendship and rivalry while protecting the island's magic [1]. - Episodes of Unicorn Academy will air on Sundays at 9 a.m. (ET/PT) for four consecutive weeks [1]. - Vida the Vet centers on a 10-year-old girl named Vida who aspires to be a veterinarian, helping animals in her new town of Sweetwood [2]. - Episodes of Vida the Vet will be broadcast Monday-Thursday at 10 a.m. (ET/PT) throughout July [2]. Company Overview - Spin Master Corp. is a leading global children's entertainment company known for creating engaging play experiences across toys, entertainment, and digital games [3]. - The company is recognized for its award-winning brands such as PAW Patrol, Melissa & Doug, Bakugan, and Rubik's Cube, and has a strong presence in digital games with 70 million active users monthly [3]. - Spin Master operates 29 offices in nearly 20 countries and employs over 2,500 team members globally [3]. Nickelodeon Brand - Nickelodeon, now in its 46th year, is the leading entertainment brand for kids, focusing on diverse programming and consumer products [4]. - The brand encompasses television programming, digital experiences, publishing, and feature films, and is part of Paramount's global portfolio of multimedia entertainment brands [4].

Company Overview - AirSculpt Technologies, Inc. (AIRS) shares increased by 8.7% to $5.25 in the last trading session, supported by higher-than-average trading volume [1] - The stock has gained 8.3% over the past four weeks, driven by stronger profitability and early success from its go-to-market strategy [1] Earnings Expectations - The company is projected to report quarterly earnings of $0.02 per share, reflecting a year-over-year decline of 77.8% [2] - Expected revenues are $45.64 million, which is a decrease of 10.5% compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for AirSculpt Technologies has been revised 100% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [3] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, suggesting potential for further strength in AIRS [3] Industry Comparison - AirSculpt Technologies is classified under the Zacks Technology Services industry, which includes other companies like Ibotta (IBTA) [4] - Ibotta's consensus EPS estimate has remained unchanged at $0.18, representing a year-over-year increase of 113.6% [5] - Ibotta has a Zacks Rank of 3 (Hold), while AirSculpt Technologies holds a Zacks Rank of 2 (Buy) [4][5]

Core Viewpoint - AirSculpt Technologies, Inc. has successfully completed a common stock offering, generating net proceeds of approximately $13.8 million, which will be used to prepay $10 million of its outstanding term loan debt, enhancing its capital structure and financial flexibility [1][2]. Financial Performance - The company has prepaid $10 million of its outstanding debt, improving its capital structure [1][2]. - After the stock offering, AirSculpt has 62,436,670 shares of common stock outstanding [2]. - The company retains full availability of $5 million under its revolving credit facility after making a remaining payment of $2.9 million on June 16, 2025 [2]. Strategic Initiatives - The prepayment of debt is part of the company's strategy to advance its transformation and position itself for sustained long-term growth in revenue and profitability [2]. - The company does not anticipate the need for additional material capital raises this year, assuming no significant changes in the macroeconomic environment [1]. Product Offering - AirSculpt provides a next-generation body contouring treatment that is minimally invasive, designed to optimize comfort and precision, allowing for quick healing with minimal bruising and precise results [3].

MIAMI BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the closing of its previously announced underwritten public offering of 3,160,000 shares of common stock. In addition, the underwriter has exercised in full its option to purchase an additional 474,000 shares of common stock. The proceeds from the offering, after estimated expenses, are estimated to be approx ...